NEXGEL interim CEO buys $732,688 in stock at premium
Alpha Vantage · Investing.com Nigeria · · AI-summarised by FinFlash
NEXGEL interim CEO Brian Kieser, through Sequence LifeScience, Inc., acquired 133,216 common shares for $732,688 in a private placement, paying $5.50 per unit of stock plus warrant — a premium to the current share price. The transactions followed a 1-for-20 reverse split and approval to increase authorized shares.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.